详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

137| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd. [2]The Southwest Hospitai of Amu Chongqing,Chongqing,China,400083 [3]West China Hospital,Sichuan University Chengdu,Sichuan,China,610000 [4]The Affiliated Hospital of Southwest Medical University Luzhou,Sichuan,China,646000 [5]The First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032 [6]Second Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650101

研究目的：

This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

资源点击量：53661 今日访问量：0 总访问量：1665 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题